1. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006; 232 (5): 123–38.
2. Burstein HJ, Harris LN, Marcom PK et al. Trastuzumab and vinorelbine as first-line therapy for HER-2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algoritm. J Clin Oncol 2003; 21 (15): 2889–95.
3. Konecny G, Pauletti G, Pergram M. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive breast cancer. J Natl Cancer Inst 2003; 95 (2): 142–53.
4. Jones A. Combining trastuzumab (Herceptin®) with hormonal therapy in breast cancer: what can be expected and why? Ann Oncol 2003; 14 (12): 1697–704.
5. Johnston SRD, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003; 3 (11): 821–31.
6. Jackisch C. HER-2 positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologust 2006; 11 (Suppl.): 34–41.
7. Shou J, Massarwen S, Osborne CK et al. Mechanisms of tamoxifen resistance. increased estrogen receptor-HER-2/neu cross-talk in ER/HER-2-positive breast cancer. J Natl Cancer Inst 2004; 96 (12): 926–35.
8. Ocana A, Cruz J, Pandiella A. Trastuzumab and antiestrogen therapy. Focus on mechanisms of action and resistance. Am J Clin Oncol 2006; 29 (1): 90–5.
9. Toi M, Horiguchi K, Bando H et al. Trastuzumab: updates and future issues. Cancer Chemother Pharmacol 2005; 56 (Suppl. 1): s94–9.
10. Prat A, Baselga J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER-2. Nat Clin Prac Oncol 2008; 5 (9): 531–42.
11. Konecny GE, Pergram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab treated breast cancer cells. Cancer Res 2006; 66 (3): 1630–9.
12. Xia W, Mullin RJ, Keith BR et al. Antitumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erb2 and downstream Erk1/2 and EKT pathway. Oncogene 2002; 21 (41): 6255–63.
13. Nelson MH, Dolder DR. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 2006; 40 (2): 261–9.
14. Rusnak DW, Lackey K, Affleck K et al. The effect of the novel, reversible epidermal growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1 (2): 85–94.
15. Gomez HL, Chavez MA, Doval DC et al. Results from a phase II randomized study of lapatinib as first-line treatment for patient with HER-2-amplified locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl. 1): abstract 1090.
16. Burstein HJ, Storniolo AM, Franco S et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER-2-positive and HER-2-negative advanced or metastatic breast cancer. Ann Oncol 2008; 19 (6): 1068–74.
17. Iwata H, Toi M, Fujiwara Y et al. Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl. 1): abstr. 1091.
18. Johnston SRD, Trudeau M, Kaufman B et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008; 26 (7): 1066–72.
19. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysis. Breast Cancer Res Treat 2008 Jan 11. Epub ahead of print.
20. Di Leo A, Gomez H, Aziz Z et al. Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: a phase III randomized, double-blind study of 580 patients. J Clin Oncol 2007; 25 (18S): abstr. 1011.
21. Cameron DA, Stein S. Drug insight: intracellular inhibitors of HER-2-clinical development of lapatinib in breast cancer. Nat Clin Prac Oncol 2008; 5 (9): 512–9.
22. Clayton AJ, Danson S, Lolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91 (4): 639–43.
23. Montagna E, Cancello G, D’Agostino D et al. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. Cancer Chemother Pharmacol 2008 Apr 1. Epub ahead of print.
24. Torresi U. Trastuzumab-treated advanced breast cancer patients and brain metastases: just a little alert. Ann Oncol 2008; 19 (1): 191.
25. Stemmler HJ, Schmitt M, Willems A et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER-2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007; 18 (1): 23–82.
26. Burris HA. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/erbB-2 inhibitor lapatinib. Oncologist 2004; 9 (Suppl. 3): 10–5.
27. Lin NU, Carey LA, Liu MC et al. Phese II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26 (12): 1993–9.
28. Cianfrocca ME, Rosen ST, von Roenn JH et al. A phase I trial of pegylated liposomal anthracycline and lapatinib (L) combination in the treatment of metastatic breast cancer (MBC): first evaluation of an anthracycline and lapatinib combination in the treatment MBC. J Clin Oncol 2007; 25 (S18): abstr. 1079.
29. Hobday TJ, Perez EA. Molecularly targeted therapies for breast cancer. Cancer Control 2005; 12 (2): 73–81.
30. Xia W, Bacus S, Hegde P et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 2006; 103 (20): 7795–800.
31. Wenham N, D’Hondt V, Piccart MJ. HER-2-positive breast cancer: from trastuzumab to innovatory anti-HER-2 strategies. Clin Breast Cancer 2008; 8 (1): 38–49.
32. Moy B, GossPE. TEACH: Tykerb evaluation after chemotherapy. Clin Breast Cancer 2007; 7 (6): 489–92.
33. Guarneri V, Frassoldati A, Piacentini F et al. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER-2-positive operable breast cancer (CHERLOB trial). Clin Breast Cancer 2008; 8 (2): 192–4.
34. Frassoldati A, Guarneri V, Piacentini F et al. Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER-2-negative operable breast cancer; a doubl-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB). Clin Breast Cancer 2008; 8 (1): 97–100.
35. Moy B, GossPE. Lapatinib: current status and future directions in breast cancer. Oncologist 2006; 11 (10): 1047–57.
36. Bacus SS, Trusk P, Lyass L et al. Inhibition of ErbB1/2 by small molecule tyrosine kinase inhibitors, but not trastuzumab, affects metabolic pathways: implications to cardiac toxicity. Breast Cancer Res Treat 2006; 100 (Suppl. 1): abstr. 304.
37. Perez EA, Byrne JA, Hammond IW et al. Results of analysis of cardiac function in 2,812 patients treated with lapatinib. J Clin Oncol 2006; 24 (S18): abstr. 583.
38. Allen LF, Eiseman IA, Fry DW, Lenehan PF. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol 2003; 30 (5 Suppl. 16): 65–78.
39. Nemunaitis J, Eiseman IA, Cunningham C et al. Phase I clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res 2005; 11 (10): 3846–53.
40. Garland LL, Hidalgo M, Mendelson D et al. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 2006; 12 (14Pt 1): 4274–82.
41. Rabindran SK, Disfani CM, Rosfjord EC et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004; 64 (11): 3958–65.
42. Wohg KK, Fracasso PM, Bukowski RM et al. HKI-272, an irreversible pan-erbB receptor tyrosine kinase inhibitor; preliminary phase 1 results in patients with solid tumors. J Clin Oncol 2006; 24 (S18): abstr. 3018.
43. Burstein HJ, Awada A, Badwe R et al. HKI-272, an irreversible pan-erbB receptor tyrosine kinase inhibitor; preliminary phase 2 results in patients with advanced breast cancer. Breast Cancer Res Treat 2007; 106 (Suppl. 1): abstr. 6061.
44. Emanuel SL, Hughes TV, Adams M et al. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol Pharmacol 2008; 73 (2): 338–48.
45. Lan KH, Lu CH, Yu D. Mechanisms of trastuzumab resistance and their clinical implications. Ann N Y Acad Sci 2005; 1059: 70–5.
46. Piccart M. Circumventing de novo and required resistance to trastuzumab: new hope for the care of ErbB-positive breast cancer. Clin Breast Cancer 2008; 8 (Suppl. 3): S100–13.
47. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER-2-overexpressing breast cancer. Ann Oncol 2007; 18 (6): 977–84.
48. Friedlander E, Barok M, Szolossi J, Vereb G. ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunology Letters 2008; 116 (2): 126–40.
49. Price-Schiavi SA, Jepson S, Li P. Rat Muc4 (sialomucin complex) reduces binding of anti- ErbB antibodies to tumor cell surfaces, a potential mechanism for Herceptin resistance. Int J Cancer 2002; 99 (6): 783–91.
50. Nagy P, Friedlender E, Tanner M et al. Decreased accessibility and lack of activation of ErbB in JIMT-1, a herceptin-resistant, MUC-4 expressing breast cancer cell line. Cancer Res 2005; 65 (2): 473–82.
51. Molina MA, Saez R, Ramsey EE et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 2002; 8 (2): 347–53.
52. Scaltriti M, Rojo F, Ocana A et al. Expression of p95HER-2, a truncated form of the HER-2 receptor, and response to anti-HER-2 therapies in breast cancer. J Natl Cancer Inst 2007; 99 (8): 628–38.
53. Borras AM, Rogers A, Kuang Y et al. Identification of novel splice variants in breast cancer. J Clin Oncol 2008; 26 (Suppl.): abstr. 22010.
54. Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors expressing HER-2. Clin Cancer Res 2004; 10 (17): 5650–5.
55. Diermeier S, Norvath G, Knuechel-Clarke R et al. Epidermal growth factor receptor coexpression modulates sysceptibility to Herceptin in HER-2/neu overexpressing breast. Exp Cell Res 2005; 304 (2): 604–19.
56. Brockhoff G, Heckel B, Schmidt-Bruecken E et al. Differential impact of cetuximab, pertuzumab and trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif 2007; 40 (4): 488–507.
57. Bender LM, Nahta R. HER-2 cross talk and therapeutic resistance in breast cancer. Front Biosci 2008; 13 (May 1): 3906–12.
58. Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002; 62 (11): 3151–8.
59. Valabrega G, Montemurro F, Sarotto I et al. TGFalpha expression impairs trastuzumab-induced HER-2 downregulation. Oncogene 2005; 24 (18): 3002–10.
60. Robinson AG, Turbin D, Thomson T et al. Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease. Clin Breast Cancer 2006; 7 (3): 254–61.
61. Wang SE, Xiang B, Guix M et al. Transforming growth factor α engages TACE and ErbB3 to activate PI3K/Akt in erbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 2008 doi:10.1128/MCB.00787-08.14. July 2008. Epub ahead of print.
62. Press MF, Finn RS, Di Leo A et al. Correlation of HER-2 gene amplification, HER-2 and EGFR ex * pression (protein and mRNA) with lapatinib efficacy in women with metastatic breast cancer. J Clin Oncol 2008; 26 (Suppl.): abstr. 1007.
63. Casa AJ, Dearth RK, Litzenburger BC et al. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 2008; 13: 3273–87.
64. Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth – inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 2004; 108 (3): 334–41.
65. Nahta R, Yuan LX, Zhang B et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65 (23): 11118–28.
66. Spector NL, Xia W, Burris 3rd H et al. Study of biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23 (11): 2502–12.
67. Yakes FM, Chinratanalab W, Ritter CA et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62 (14): 4132–41.
68. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6 (2): 117027.
69. Berns K, Horlings HM, Henessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12 (4): 395–402.
70. Pegram M, Perez EA, Piccart M, Spector N. Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007. Clin Brest Cancer 2008; 8 (Suppl. 3): S131–41.
71. Nahta R, Takanashi T, Ueno NT et al. P27 (kip1) downregulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004; 64 (11): 3981–6.
72. Singer CF, Kostler WJ, Hudelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standard and future strategies. Biochim Biophys Acta 2008 Mar 4. Epub ahead of print.

И.Н.Огнерубова

Кафедра онкологии ГОУ ДПО РМАПО, Москва